(MarketWatch) -- Novartis AG is working on several drugs that will combine its new heart medicine Rasilez and another drug in a single pill to prepare for the expected loss of revenue when the patent of its best-selling drug Diovan will expire in four years, the Swiss drugmaker said Wednesday.
